Obesity now affects over 1 billion people worldwide, driving millions of deaths and trillions in costs-yet new WHO guidance offers hope through GLP-1 therapies like semaglutide and tirzepatide.

Released December 1, 2025, this first-ever global guideline conditionally recommends these drugs for long-term adult obesity treatment (BMI ≥30 kg/m²), excluding pregnant women, as part of comprehensive care including diet, exercise , and professional support.

Obesity, recognized as a chronic and relapsing disease, significantly heightens risks for cardiovascular diseases like heart attacks and strokes, type 2 diabetes, various cancers, fatty liver disease, osteoarthritis, sleep apnea, and worsened infectious disease outcomes-potentially doubling global cases by 2030 without urgent interventi

See Full Page